Peroxiredoxin 4: A Potential Drug Target and Biomarker (G10549)

Target Name: PRDX4

NCBI ID: G10549

PRDX4

Peroxiredoxin 4: A Potential Drug Target and Biomarker

Peroxiredoxin 4 (PRDX4) is a protein that is expressed in various tissues and cells in the body. It is a member of the NAD+-dependent monooxygenase (MONOX) superfamily and is involved in the detoxification of peroxides, which are reactive oxygen species that can cause damage to cellular components. PRDX4 is also known as peroxiredoxin 4 and is a protein that is expressed in various tissues and cells in the body.

The Importance of PRDX4

PRDX4 is involved in the detoxification of peroxides, which are reactive oxygen species that can cause damage to cellular components. Peroxides are generated by cellular processes such as cellular respiration and metabolism and can also be generated by external factors such as exposure to radiation or chemicals. These peroxides can cause damage to cellular components such as DNA, RNA, and proteins, leading to a wide range of cellular and tissue changes.

PRDX4 plays an important role in the detoxification of peroxides by participating in the antioxidant response. It is a key enzyme in the monooxygenase (MONOX) superfamily, which is responsible for the production of reactive oxygen species (ROS) from monooxygen precursors. PRDX4 is involved in the production of ROS by reacting with oxygen precursors such as NAD+ and FAD.

The Potential Role of PRDX4 as a Drug Target

The discovery of PRDX4 as a potential drug target has significant implications for the development of new treatments for a variety of diseases. PRDX4 is involved in the detoxification of peroxides, which can lead to the production of reactive oxygen species (ROS) that can cause damage to cellular components. By targeting PRDX4, researchers may be able to develop new treatments for diseases caused by the production of ROS, such as cancer, neurodegenerative diseases, and autoimmune disorders.

PRDX4 is also a potential biomarker for a variety of diseases. The production of ROS by PRDX4 can be used as a diagnostic marker for diseases caused by the production of ROS. For example, the production of ROS by PRDX4 may be increased in the cells of cancer cells, making them more resistant to chemotherapy and radiation. This could make these treatments more effective and reduce the risk of side effects.

PRDX4 is also a potential target for new therapies for respiratory diseases. The production of ROS by PRDX4 has been linked to the development of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. By targeting PRDX4, researchers may be able to develop new treatments for these diseases that are effective in reducing the production of ROS and improving respiratory function.

Conclusion

PRDX4 is a protein that is involved in the detoxification of peroxides and the production of reactive oxygen species (ROS). It is a key member of the NAD+-dependent monooxygenase (MONOX) superfamily and plays an important role in the antioxidant response. The potential discovery of PRDX4 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of PRDX4 in the detoxification of peroxides and the production of ROS, as well as its potential as a drug target and biomarker.

Protein Name: Peroxiredoxin 4

Functions: Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Regulates the activation of NF-kappa-B in the cytosol by a modulation of I-kappa-B-alpha phosphorylation

The "PRDX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets